

20 May 2026

MACH7 SIGNS NEW CUSTOMER, SHORTENS SALES & DEPLOYMENT TIMEFRAME

- American Radiologist Network Inc. (AMRADNET) signs 5-year annual subscription licence for eUnity Viewer
- Initial contract value of A\$1.7M based on minimum of 0.675M studies per annum
- Volumes projected to exceed 1M studies during 5-year term
- Sales cycle and time to FPU¹ significantly reduced

Mach7 Technologies Limited (“Mach7” or the “Company”) (ASX:M7T), a healthcare software company that enables healthcare organisations to securely store, access and share diagnostic imaging across disparate systems, today announces the signing of a new customer contract with leading US-based teleradiology provider American Radiologist Network Inc. (“AMRADNET”).

AMRADNET is a US-based teleradiology company whose SaaS-based Radiology Informatics Portal connects US board-certified radiologists with healthcare facilities for remote imaging interpretation and reporting. Since its founding in 2004, the company has expanded its client base from long-term acute care and skilled nursing institutions to hospitals, outpatient centres, urgent care centres, and diagnostic clinics. AMRADNET is further extending its reach into cardiology, neurology and broader telemedicine services.

The new contract is effective from 20 May 2026² and FPU is expected within 45 days, a significant reduction on Mach7’s typical 12-month deployment timeline. This reflects the commercial transformation underway at the Company with the removal of silos and restructuring of the sales and services teams.

Mach7 CEO and Managing Director Teri Thomas said: “AMRADNET is building a scalable and rapidly growing teleradiology platform, and this agreement reflects a shared commitment to expanding access to high-quality diagnostic care across the US healthcare market. The speed from evaluation to expected first productive use highlights both the operational focus of the AMRADNET team and the strength of the eUnity platform in supporting fast-moving, high-volume imaging environments. We look forward to supporting AMRADNET’s continued growth as they expand their clinical reach and imaging volumes over time.”

Released on authority of the Board by Teri Thomas, Managing Director and Chief Executive Officer.

¹ First Productive Use (FPU)

² 19 May 2026 in the US.

For more information, contact:

Investor Relations
Françoise Debelak
+61 (0) 412 292 977
ir@mach7t.com

About Mach7 Technologies :

Mach7 Technologies (ASX:M7T) provides enterprise imaging software that enables healthcare organizations to manage, access and share diagnostic imaging data across complex environments. The Mach7 platform combines a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer and the Flamingo suite of modules, expanding capabilities across workflow, interoperability and data management to support a more complete view of the patient record. Together, these capabilities position Mach7 to support the evolution of enterprise imaging toward a more unified, longitudinal patient record that integrates clinical data and diagnostic imaging. Built for interoperability and scalability, Mach7 supports emerging AI-driven clinical workflows and is increasingly aligned with leading cloud ecosystems, including Amazon Web Services (AWS). The Company serves a global customer base including integrated delivery networks, national health systems and specialist imaging providers. Visit mach7t.com for more information.

Forward-looking statements

This announcement may contain forward-looking statements regarding the Company's financial position, business strategy and objectives (rather than being based on historical or current facts). Any forward-looking statements are based on the current beliefs of the Company's management as well as assumptions made by, and information currently available to, the Company's management. Forward-looking statements are inherently uncertain and must be read accordingly. There can be no assurance that some or all of the underlying assumptions will prove to be valid.

All data presented in this announcement reflects the current views of the Company with respect to future events. Forward-looking statements are subject to risk, uncertainties and assumptions relating to the operations, results of operations, growth strategy and liquidity of the Company. To the maximum extent permitted by law, the Company, its officers, employees and agents do not accept any obligation to release any updates or revisions to the information (including any forward-looking statements) in this announcement to reflect any change to expectations or assumptions; and disclaim all responsibility and liability for any loss arising from reliance on this announcement or its contents.



Mach7 Technologies Limited (ASX:M7T) ABN: 26 007 817 192
Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000
T: +61 1300 384 692
www.mach7t.com